CanSino Biologics Inc's (CanSinoBIO) Covid-19 vaccine showed 65.7 percent efficacy in preventing symptomatic cases and a 90.98 percent success rate in stopping severe disease in an interim analysis of global trials, Pakistan's health minister said on Monday.

The positive data moves the vaccine, jointly developed by a research institute affiliated with the Chinese military, a step closer to becoming China's third successful shot for the disease...